HB3130, the FACTS Act, is a federal education-and-public-health bill aimed at preventing youth misuse and overdose of synthetic opioids, especially fentanyl. It would create a competitive, three-year pilot grant program for partnerships between schools and public health agencies to fund evidence-based prevention, education, treatment, and recovery activities for secondary school-aged children. Eligible uses include classroom materials, staff training, family outreach, multimedia campaigns, peer-to-peer counseling, and partnerships with nonprofit organizations experienced in substance use prevention and recovery.
The bill also creates an interagency task force led by the Department of Health and Human Services, in consultation with the Department of Education, to identify best practices and develop a national strategy for addressing synthetic opioid misuse and overdose among youth. In addition, it amends the Elementary and Secondary Education Act to require opioid-prevention training and planning in school and state education programs, and it directs federal education data systems and public health surveys to collect more information on counterfeit and synthetic opioid exposure among youth. It further authorizes the use of naloxone and related opioid-response activities in school-based health centers and calls for evaluation of overdose reporting systems.
If enacted, the bill would affect several federal statutes and programs, including the Elementary and Secondary Education Act of 1965, the Education Sciences Reform Act of 2002, and the Public Health Service Act. It would expand the role of the Department of Education, CDC, NIH/NIDA, and HHS in school-based opioid prevention and data collection, while also creating new grant opportunities for local educational agencies, state educational agencies, Tribal and Bureau of Indian Education schools, and public health partners. The bill is structured to supplement, not replace, existing federal or state funding.
Because there are no committee transcripts or recorded votes in the provided material, the available sentiment is limited to the bill’s bipartisan sponsorship and its public-health framing. The bill appears to be presented as a preventive, school-centered response to a widely recognized overdose crisis, with emphasis on evidence-based practices, family engagement, and coordination across agencies. The inclusion of bipartisan cosponsors suggests at least some cross-party support.
No specific points of contention are documented in the provided record, but the bill’s scope could raise questions about federal involvement in local school policy, the use of federal funds for school-based health interventions, and the balance between prevention, treatment, and data collection mandates. The bill also places priority on areas with higher youth illicit drug use and requires culturally responsive and linguistically appropriate programming, which may be important implementation issues for schools and agencies.
The bill would create new federal grant and coordination programs focused on synthetic opioid prevention in schools, while amending existing education and public health laws to require opioid-awareness training, planning, and data collection. It would modify the Elementary and Secondary Education Act to incorporate fentanyl and synthetic opioid prevention into school personnel professional development and state/local education plans, and it would expand federal survey and reporting requirements to track youth exposure, awareness, and access to counterfeit or synthetic opioids. It also authorizes naloxone-related activities in school-based health centers and provides funding for evaluation and technical assistance.
The overall sentiment appears supportive and prevention-oriented. The bill is framed as a bipartisan response to youth fentanyl and synthetic opioid harms, with sponsors from both parties and a focus on schools, families, public health agencies, and evidence-based interventions. No votes or hearing testimony are provided, so there is no recorded opposition in the supplied materials, but the bill’s public-health and school-safety emphasis suggests it is intended to attract broad support.
No explicit contention is documented in the provided materials. Potential areas of debate, based on the bill text, include whether federal law should direct school-level opioid prevention programming, the extent of required data collection on youth drug use, the role of naloxone in school-based health centers, and how much discretion states and local districts should retain in designing prevention and recovery services. Implementation burdens, funding adequacy, and privacy concerns around student survey data could also be points of concern for some stakeholders.